Sharekhan

Alembic Ltd

Thu 13/03/2025,15:59:6 | NSE : ALEMBICLTD

₹ 92.59-1.11 (-1.18%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 94.30

Previous Close

₹ 93.70

Volume

263126

Mkt Cap ( Rs. Cr)

₹2377.54

High

₹ 94.69

Low

₹ 92.30

52 Week High

₹ 169.00

52 Week Low

₹ 78.10

Book Value Per Share

₹ 87.48

Dividend Yield

2.58

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Alembic Ltd

Your Vote -

Buy

81.77%

Hold

2.46%

Sell

15.76%

81.77%

203 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

92.59

150

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

150

Option Chain

Analyzes market sentiment, predicts Alembic Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Alembic Ltd. - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    25 Feb 2025, 10:06AM ALEMBIC LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
  • Alembic Ltd. - Retirement

    25 Feb 2025, 10:04AM Alembic Limited has informed the Exchange about Retirement
  • Alembic Ltd. - Announcement under Regulation 30 (LODR)-Retirement

    25 Feb 2025, 10:02AM Please find attached herewith intimation for completion of tenure of Mr. Sameer Khera, Independent Director of the Company w.e.f the end of the day on
  • Alembic Ltd. - Copy of Newspaper Publication

    20 Feb 2025, 3:16PM Alembic Limited has informed the Exchange about Copy of Newspaper Publication
  • Alembic Ltd. - Notice Of Shareholders Meetings-XBRL

    19 Feb 2025, 3:41PM Alembic Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot
  • Alembic Ltd. - Shareholders meeting

    19 Feb 2025, 3:39PM Alembic Limited has informed the Exchange regarding Notice of Postal Ballot
  • Alembic Ltd. - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    19 Feb 2025, 3:38PM Please find enclosed herewith the copy of postal ballot notice dated 7th February, 2025 for seeking approval of members through e-voting in respect of
  • Alembic Ltd. - Copy of Newspaper Publication

    8 Feb 2025, 12:50PM Alembic Limited has informed the Exchange about Copy of Newspaper Publication
  • Alembic Ltd. - Integrated Filing- Financial

    7 Feb 2025, 6:27PM Integrated Filing (Financial) - Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2024
  • Alembic Ltd. - Integrated Filing (Financial)

    7 Feb 2025, 6:26PM We are submitting herewith the integrated Filing (Financial) - Unaudited Financial Results for the quarter and nine months period ended 31st December,
  • Alembic Ltd. - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    7 Feb 2025, 6:15PM ALEMBIC LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
  • Alembic Ltd. - Change in Director(s)

    7 Feb 2025, 6:12PM Alembic Limited has informed the Exchange regarding Change in Director(s) of the company.
  • Alembic Ltd. - Announcement under Regulation 30 (LODR)-Change in Directorate

    7 Feb 2025, 6:12PM Please find enclosed herewith the intimation under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for change
  • Alembic Q3 net profit zooms 127.55% at Rs 25.69 cr

    7 Feb 2025, 6:01PM The company reported standalone net profit of Rs 25.69 crore for the quarter ended December 31, 2024 as compared to Rs 11.29 crore in the same period
  • Alembic Ltd. - Financial Result Updates

    7 Feb 2025, 5:51PM Alembic Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Alembic Ltd. - Unaudited Financial Results For The Quarter And Nine Months Period Ended 31St December, 2024

    7 Feb 2025, 5:50PM Please find enclosed herewith the Standalone and Consolidated Financial Results of the Company for the quarter and nine months period ended 31st Decem
  • Alembic Ltd. - Outcome of Board Meeting

    7 Feb 2025, 5:45PM Alembic Limited has informed the Exchange regarding Outcome of Board Meeting held on February 07, 2025.
  • Alembic Ltd. - Board Meeting Outcome for Outcome Of Board Meeting

    7 Feb 2025, 5:45PM Please find enclosed herewith outcome of Board Meeting held on 7th February, 2025.
  • Alembic Ltd. - Board Meeting Intimation

    29 Jan 2025, 2:22PM Alembic Limited has informed the Exchange about Board Meeting to be held on 07-Feb-2025 to consider and approve the Quarterly Unaudited Financial resu
  • Alembic Ltd. - Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Nine Months Period En

    29 Jan 2025, 2:20PM ALEMBIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 ,inter alia, to consider and approve
  • Alembic Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    20 Jan 2025, 3:50PM As of December 2024, 70.88% is owned by Indian Promoters and 29.12% by Public. <p align=justify> Top five Promoters holding highest number of shares o
  • Alembic Ltd. - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    17 Jan 2025, 2:01PM ALEMBIC LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
  • Alembic Ltd. - Demise

    17 Jan 2025, 1:58PM Alembic Limited has informed the Exchange regarding Demise of Mr. Mayank Amin, Non- Execut of the company on January 16, 2025.
  • Alembic Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Jan 2025, 7:34PM Please find enclosed herewith a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 31st
  • Alembic Ltd. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Jan 2025, 7:34PM Alembic Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Alembic Ltd. - General Updates

    1 Jan 2025, 12:59PM Alembic Limited has informed the Exchange about General Updates
  • Alembic Ltd. - Intimation For Change Of Name Of Registrar And Share Transfer Agent ('RTA') Of The Company

    1 Jan 2025, 12:55PM Please find enclosed herewith the intimation informing that the RTA of the Company has changed their name from \Link Intime India Private Limited\ to
  • Alembic Ltd. - Trading Window-XBRL

    27 Dec 2024, 6:11PM Alembic Limited has informed the Exchange about Closure of Trading Window
  • Alembic Ltd. - Trading Window

    27 Dec 2024, 6:09PM Alembic Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Sun pharma, Alembic

    31 Jul 2023 , 10:34AM Sun Pharma is recalling 12,336 bottles of Buprenorphine Sublingual tablets in the US market due to manufacturing issues. Similarly, it is recalling 7,313 bottles of Methylphenidate Hydrochloride tablets. Alembic Pharma is recalling 2,844 bottles of Diclofenac Sodium Topical Solution in the US. These are class II recalls. Negative read through
  • Sun Pharmaceutical Industries, Alembic

    20 Apr 2021 , 10:43AM Sun Pharma, Alembic: As per media reports, Sun Pharma is recalling 91211 pre-filled syringes of Ganirelix Acetate injection on grounds of “failed impurities/degradation specifications”. The USFDA has classified this recall as a Class II recall. Sun pharma is also recalling 2520 bottles of diabetes drug, Metformin HCl Extended-Release tablets, in the US market due to “failed moisture limits: Out of specification for water content”. The USFDA has classified this recall as a class 3 recall. Both the recalls done by the company are unlikely to have any material impact on the financials of the company. Alembic Pharmaceuticals is recalling 12,288 bottles of Telmisartan Tablets citing reasons of “label mix up”. The recall is unlikely to have any material impact on the financial performance of the company.
  • Cadila Healtcare, Alembic

    31 Mar 2021 , 10:40AM As per media reports, Cadila’s US arm Zydus Pharmaceuticals (USA) is voluntarily recalling acyclovir sodium injection in the US which is used for treatment of herpes infections in immunocompromised patients, after receiving several complaints of crystallisation in vials. Alembic is also voluntarily recalling its blood pressure drug - telmisartan, in the US due to a mislabelling error. As both the recalls are voluntary in the nature , they are unlikely to have any material impact on the financial performance of the companies.
  • Alembic board to consider buyback; stk up

    19 Jan 2018 , 12:50PM Alembic rises over 9% to Rs64.5, as board to consider buyback of equity shares

Key fundamentals

Evaluate the intrinsic value of Alembic Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 817.9082 828.986 1013.8512 827.0969 483.101
Liabilities 817.9082 828.986 1013.8512 827.0969 483.101
Equity 51.3564 51.3564 51.3564 51.3564 51.3564
Gross Profit 56.2489 38.005 12.9155 10.7291 3.7195
Net Profit 92.888 79.2703 85.7147 13.364 93.5526
Cash From Operating Activities 25.3308 34.6964 -21.8651 -212.5845 6.1222
NPM(%) 61.01 64.36 112.82 18.48 126.95
Revenue 152.25 123.1576 75.9728 72.3 73.6893
Expenses 96.0011 85.1526 63.0573 61.5709 69.9698
ROE(%) 4.13 3.52 3.81 0.59 4.16

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
05 Aug 2024 2.4 120 2.59 87.65
03 Aug 2023 2.2 110 2.59 64.55
12 Sep 2022 1.8 90 2.59 75.3
29 Jul 2021 0.2 10 2.59 132.85
29 Jul 2020 0.6 30 2.59 51.95
18 Sep 2019 0.2 10 2.59 46.05
27 Jul 2018 0.2 10 2.59 53.35
19 Jul 2017 0.2 10 2.59 45.95
01 Aug 2016 0.15 7.5 2.59 39.25
03 Aug 2015 0.15 7.5 2.59 34.9
04 Aug 2014 0.15 7.5 2.59 18
26 Aug 2013 0.2 10 2.59 18.2
21 Jul 2010 0.5 25 2.59 47.45
17 Jul 2009 0.4 20 2.59 36.55
17 Jul 2008 1.5 75 2.59 62.85
13 Aug 2007 1 50 2.59 57.75
16 Aug 2006 5 50 2.59 394.85
16 Aug 2005 3 30 2.59 256.05
29 Jul 2004 2 20 2.59 165.4
07 Aug 2003 4.5 45 2.59 270.95
29 Aug 2002 0 45 2.59 126.75
01 Jun 2001 0 35 2.59 139.6
0 35 2.59 296.5
0 30 2.59 2125.2
0 24 2.59 580.2
0 24 2.59 845

Peers

Other companies within the same industry or sector that are comparable to Alembic Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 52.95 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 192.93 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 99.44 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 181.91 -239.30 0.00

Company Info

YEAR EVENTS 1907 - The Company was Incorporated at Vadodara. The Company manufacture chemicals, pharmaceuticals, injections, penicillin, antibiotics, sulphuric acid, superphosphate and other fertilisers, generating electricity, manufacture of electronic items, running of hospitals and health care units, etc. 1938 - The authorised capital was Rs 20 lakhs divided into 10,000-6 1/4% preference shares of Rs 100 each and 10,000 No. of equity shares of Rs 100 each. 5,000 preference shares and all equity shares were issued and subscribed. 1942 - 5,000-6% preference shares were issued and subscribed. 1944 - The authorised capital was increased to Rs 50 lakhs by the creation of 30,000 shares of Rs 100 each out of which 3,000 shares were classified as equity shares and issued to the shareholders in the proportion 3:10. 1946 - The Company issued 2,000 No. of equity shares as rights at a premium of Rs 150 per share in the proportion 2:13. 1947 - 5,000 unclassified shares were converted into equity, shares and they were issued as rights at a premium of Rs 150 per share in the proportion 1:3. 1948 - 5,000 unclassified shares were converted into equity shares and issued as bonus in the proportion 1:4. 1949 - The authorised capital was increased to Rs 1 crore by creation of 5,000-6% third preference shares of Rs 100 each and 45,000 unclassified shares of Rs 100 each. Further 7,000 unclassified shares were converted into equity shares and issued as bonus in the proportion of 2:3 irrespective of class. 1958 - The authorised, issued and paid-up capital stood at Rs 100,00,000 and Rs 80,00,000 respectively as at 31st December. 1959 - 20,000 Right Equity shares offered at par in prop. 1:4 to all classes. In 1961, 10,000 Right Equity shares offered at par in prop. 1:1 to classes. 1962 - 9,500 Bonus equity shares issued in prop; 1:10, 40,000 Right Equity shares offered at a prem. of Rs 30 per share in the prop. 4:11 irrespective of class. 1966 - In Dec. 48,167 Bonus Equity shares issued in prop. 1:3. 12,278 No. of equity shares issued without payment in cash to members of Alembic Distributors Ltd., Mumbai and Alembic distributing Agency, Bangalore on their merger. 1967 - The amalgamation on Alembic Distributors, Ltd., with the Company from 1st January, was sanctioned by the High Courts of Ahmedabad and Mumbai. The Scheme of Amalgamation of Neomer Ltd. with the Company from the appointed date 1.1.1983 was approved by the High Court of Gujarat by its Order dated 12.9.1986. 1968 - 25,080 Right Equity shares issued at par in prop. 5:41. - In March 1971, 57,487 Right Equity shares issued at par in the prop. 1:5. 1977 - 6 1/4% Pref. and 6% III Pref. shares converted to 9% redeemable Pref. shares from 1.1.1976. 5,000-5% Pref. shares redeemed at Rs 105 per shares on 1.1.1977. 1979 - The Company issued 75,000 secured debentures of Rs 100 each as rights to augment the resources of working capital. 1980 - Redeemed 1,000 Pref. shares each on 1.1.1978, 1.1.1979, 1.11.1980, 1.1.1981, 1.1.1982 and 1.1.1983. 1985 - 2,000 Pref. shares redeemed. 66,900 No. Equity shares allotted without payment in cash to the shareholders of Neomer, Ltd. on its merger. 2,000 Pref. shares redeemed. 1989 - A variety of new products were introduced under group Feed Supplements and Tonics which were well received in the market. - The Panpharm Division was started at village Panelav in Panchmahal district of Gujarat State to undertake manufacture of formulations. 1990 - A new quinolone antibacterial drug "Ciprofloxacin" was introduced in the market. - The Veterinary Division introduced certain new farm products like ascal, ruman bolus etc. during the year. - New products such as ginseng preparation and zinc and vitamin-B complex preparations were introduced in the market. - 100,000-14% non-convertible debentures were issued. These debentures are redeemable in three yearly instalments commencing from 11th May, 1995 with redemption premium of 5% payable along with the last instalment. 1991 - As a result of the research and development activities, the company developed Roxithronycin, a newer generation bulk drug. 1992 - The veterinary division introduced Cloxacillin Amoxicillin injections. - Introduction of Cloxacillin Amoxicillin injection in the market. 1993 - The Expansion of Penicillin capacity to 1000 MMU together with integrated effluent treatment plant was undertaken and series of steps were taken to instal diesel engine driven compressors for constant air supply etc. - The erstwhile Neomer, Ltd. had a licensed capacity to manufacture 6000 mt. polypropylene staple fibre. In addition to this, it was registered with D.G.T.D. for the manufacture of 1000 mt. per annum. of polypropylene multifilament yarn. - Under the broad banding policy, Neomer had obtained permission to manufacture other synthetic filament yarn i.e. polyester and nylon yarn including industrial yarn/tyre cord. - The company introduced a revolutionary antibiotic Azithromycin which is used in tissue directed antibiotic therapy. 1995 - With a view to facing this eventuality the company proposed to install gas turbine based captive Co-generations Power Unit at a total outlay of Rs 25 crores. - Two large pencillin fermentors were installed and commissioned. - "Algen, Ltd." is a subsidiary of the Company. As at 31st Dec. 10,007 No. of equity shares out of 10,013 No. of equity shares of Rs 10/- each issued by the subsidiary were held by the Company. - 164,732 No. of equity shares of Rs 100 each at a premium of Rs 850/- per share issued to the shareholders on rights basis. 1996 - 10,00,000 Pref. shares allotted on preferential basis. 1997 - The performance of the pharmaceutical division was affected by Governmental basis imposed on scrip to pencillin formulation which affected the major brand of the company. - The Company introduced Nimegesic Gel an important topical item. The Company introduced Rorid liquid for paediatric use, a ready made suspension of Roxithromycin. The Company strengthened its position by the introduction of Clarithro and basic manufacture of clarithromycin. - The company installed Peniccillin - Gas 600 m.m.u. per annum and Erythromycin 100 tpa. Also, a second line of extraction facility for erythromycin was installed. - The Alembic Herbals veterinary, a new division of veterinary business was launched in June. - The Company issued 10,00,000-16% redeemable non-convertible cumulative preference shares of Rs 100 each. These are redeemable at par on 11.2.1999. - The Company has expanded its reach in the fastest growing analgesics and anti-inflammatory segment with the launch of new molecules Rofecoxib and Celecoxib. 2000 - The Company has launched Glycodin Activ Cold & Flu Tablets. 2001 - The Company has launched its version of sildenafil citrate, under the brand name `Asigra'. The pill for erectile dysfunction is in two dosage forms of 25 mg and 50 mg as against three by most of the other players. - The Company has launched a new OTC brand, Glycodin Activ cold and flu tablets. 2002 -Gujarat High court sanctions for the merger of Bulk Drug unit of M/s Darshak Ltd with the company. -Enters into an in-licensing pact with Euroresearch for introducing Gelfix Collagen dressing sponge pads in the country. -Appoints Mr Nitin Jaywant as the President, Active Pharmaceutical Ingredients division. -Floats a new division called 'SynX' to cater to patients suffering from condition called Syndrome X . -Enters into a research pact with Chiron Corporation of US for contract research. -Gets approval from DCGI to manufacture and market Cefetamet Pivoxil tablets. -Ties up with Italian Pharma company, Euroresearch to bring its products to India. 2003 -Launches 4th generation injectable Cephalosporin Cefepime under the brand name of Cepime. -Allots equity shares to the shareholders of M/s Darshak Ltd as per the scheme of demerger. -Acquires brand and trade mark rights of obstretical care drug Yutopar from Solvay Pharmaceuticals BV, Netherlands. -Launches new division for research and development services, BioArc Research Solutions. -Forays into speciality therapeutics segment. -Signs agreement with two MNC companies for R & D division. -Lines up a rights issue of Rs.32.37crs. -Alembic Limited has informed the Exchange that the company has despatched the Offer Document and Composite application form to all the shareholders on December 22, 2003. The Rights Issue is going to open on December 30, 2003, the last date for receiving requests for split forms is January 13, 2004 and the Rights Issue will close on January 28, 2004. -The comnpany raised Rs 10 crore by placing 90-day commercial paper (CP) at 4.85 per cent with a mutual fund on March 8th. -Alembic signs MoU with Xechem International 2005 - Launches a no-calorie sugar substitute, `Zero', on February 2, 2005. 2006 -Company has splits its Face value of Shares from Rs 10 to Rs 2 2008 - Alembic Ltd has informed that the Company has acquired API manufacturing unit of Nirayu Pvt Ltd. situated at Panelav, P.O. Tajpura, Taluka Halol, Dist. Panchmahals, Gujarat. 2009 -Alembic has recommended dividend at 20% 2010 -Mr. Milin Mehta has been appointed as additional Independent Director of the company. 2011 -Mr. Ashok Tulankar has been appointed as Vice President - Production as Additional Director & Whole-Time Director on the Board of the Company 2012 -Mr. Chandrashekhar P. Buch has been appointed as an Additional - Non-Executive Independent Director of the Company 2013 -Alembic Ltd has allotted 13,35,15,914 Bonus Shares in the ratio of 1:1. -Alembic Ltd has appointed Mr. R. C. Saxena, as Additional Non-Executive Independent Director. -The Board has recommended a dividend of Re. 0.20 (10%) per Equity Share of Rs. 2 each -Alembic has announces Bonus in the Ratio of 1:1 2014 -Alembic Ltd has recommended a dividend of Re. 0.15/- (7.5%) per Equity Share of Rs. 2 each. 2018 -"HGS Wins NASSCOM Customer Service Excellence Award 2018 in Transformation Category". 2020 -Alembic gets USFDA nod for generic ophthalmic solution.

YEAR EVENTS 1907 - The Company was Incorporated at Vadodara. The Company manufacture chemicals, pharmaceuticals, injections, penicillin, antibiotics, sulphuric acid, superphosphate and other fertilisers, generating electricity, manufacture of electronic items, running of hospitals and health care units, etc. 1938 - The authorised capital was Rs 20 lakhs divided into 10,000-6 1/4% preference shares of Rs 100 each and 10,000 No. of equity shares of Rs 100 each. 5,000 preference shares and all equity shares were issued and subscribed. 1942 - 5,000-6% preference shares were issued and subscribed. 1944 - The authorised capital was increased to Rs 50 lakhs by the creation of 30,000 shares of Rs 100 each out of which 3,000 shares were classified as equity shares and issued to the shareholders in the proportion 3:10. 1946 - The Company issued 2,000 No. of equity shares as rights at a premium of Rs 150 per share in the proportion 2:13. 1947 - 5,000 unclassified shares were converted into equity, shares and they were issued as rights at a premium of Rs 150 per share in the proportion 1:3. 1948 - 5,000 unclassified shares were converted into equity shares and issued as bonus in the proportion 1:4. 1949 - The authorised capital was increased to Rs 1 crore by creation of 5,000-6% third preference shares of Rs 100 each and 45,000 unclassified shares of Rs 100 each. Further 7,000 unclassified shares were converted into equity shares and issued as bonus in the proportion of 2:3 irrespective of class. 1958 - The authorised, issued and paid-up capital stood at Rs 100,00,000 and Rs 80,00,000 respectively as at 31st December. 1959 - 20,000 Right Equity shares offered at par in prop. 1:4 to all classes. In 1961, 10,000 Right Equity shares offered at par in prop. 1:1 to classes. 1962 - 9,500 Bonus equity shares issued in prop; 1:10, 40,000 Right Equity shares offered at a prem. of Rs 30 per share in the prop. 4:11 irrespective of class. 1966 - In Dec. 48,167 Bonus Equity shares issued in prop. 1:3. 12,278 No. of equity shares issued without payment in cash to members of Alembic Distributors Ltd., Mumbai and Alembic distributing Agency, Bangalore on their merger. 1967 - The amalgamation on Alembic Distributors, Ltd., with the Company from 1st January, was sanctioned by the High Courts of Ahmedabad and Mumbai. The Scheme of Amalgamation of Neomer Ltd. with the Company from the appointed date 1.1.1983 was approved by the High Court of Gujarat by its Order dated 12.9.1986. 1968 - 25,080 Right Equity shares issued at par in prop. 5:41. - In March 1971, 57,487 Right Equity shares issued at par in the prop. 1:5. 1977 - 6 1/4% Pref. and 6% III Pref. shares converted to 9% redeemable Pref. shares from 1.1.1976. 5,000-5% Pref. shares redeemed at Rs 105 per shares on 1.1.1977. 1979 - The Company issued 75,000 secured debentures of Rs 100 each as rights to augment the resources of working capital. 1980 - Redeemed 1,000 Pref. shares each on 1.1.1978, 1.1.1979, 1.11.1980, 1.1.1981, 1.1.1982 and 1.1.1983. 1985 - 2,000 Pref. shares redeemed. 66,900 No. Equity shares allotted without payment in cash to the shareholders of Neomer, Ltd. on its merger. 2,000 Pref. shares redeemed. 1989 - A variety of new products were introduced under group Feed Supplements and Tonics which were well received in the market. - The Panpharm Division was started at village Panelav in Panchmahal district of Gujarat State to undertake manufacture of formulations. 1990 - A new quinolone antibacterial drug "Ciprofloxacin" was introduced in the market. - The Veterinary Division introduced certain new farm products like ascal, ruman bolus etc. during the year. - New products such as ginseng preparation and zinc and vitamin-B complex preparations were introduced in the market. - 100,000-14% non-convertible debentures were issued. These debentures are redeemable in three yearly instalments commencing from 11th May, 1995 with redemption premium of 5% payable along with the last instalment. 1991 - As a result of the research and development activities, the company developed Roxithronycin, a newer generation bulk drug. 1992 - The veterinary division introduced Cloxacillin Amoxicillin injections. - Introduction of Cloxacillin Amoxicillin injection in the market. 1993 - The Expansion of Penicillin capacity to 1000 MMU together with integrated effluent treatment plant was undertaken and series of steps were taken to instal diesel engine driven compressors for constant air supply etc. - The erstwhile Neomer, Ltd. had a licensed capacity to manufacture 6000 mt. polypropylene staple fibre. In addition to this, it was registered with D.G.T.D. for the manufacture of 1000 mt. per annum. of polypropylene multifilament yarn. - Under the broad banding policy, Neomer had obtained permission to manufacture other synthetic filament yarn i.e. polyester and nylon yarn including industrial yarn/tyre cord. - The company introduced a revolutionary antibiotic Azithromycin which is used in tissue directed antibiotic therapy. 1995 - With a view to facing this eventuality the company proposed to install gas turbine based captive Co-generations Power Unit at a total outlay of Rs 25 crores. - Two large pencillin fermentors were installed and commissioned. - "Algen, Ltd." is a subsidiary of the Company. As at 31st Dec. 10,007 No. of equity shares out of 10,013 No. of equity shares of Rs 10/- each issued by the subsidiary were held by the Company. - 164,732 No. of equity shares of Rs 100 each at a premium of Rs 850/- per share issued to the shareholders on rights basis. 1996 - 10,00,000 Pref. shares allotted on preferential basis. 1997 - The performance of the pharmaceutical division was affected by Governmental basis imposed on scrip to pencillin formulation which affected the major brand of the company. - The Company introduced Nimegesic Gel an important topical item. The Company introduced Rorid liquid for paediatric use, a ready made suspension of Roxithromycin. The Company strengthened its position by the introduction of Clarithro and basic manufacture of clarithromycin. - The company installed Peniccillin - Gas 600 m.m.u. per annum and Erythromycin 100 tpa. Also, a second line of extraction facility for erythromycin was installed. - The Alembic Herbals veterinary, a new division of veterinary business was launched in June. - The Company issued 10,00,000-16% redeemable non-convertible cumulative preference shares of Rs 100 each. These are redeemable at par on 11.2.1999. - The Company has expanded its reach in the fastest growing analgesics and anti-inflammatory segment with the launch of new molecules Rofecoxib and Celecoxib. 2000 - The Company has launched Glycodin Activ Cold & Flu Tablets. 2001 - The Company has launched its version of sildenafil citrate, under the brand name `Asigra'. The pill for erectile dysfunction is in two dosage forms of 25 mg and 50 mg as against three by most of the other players. - The Company has launched a new OTC brand, Glycodin Activ cold and flu tablets. 2002 -Gujarat High court sanctions for the merger of Bulk Drug unit of M/s Darshak Ltd with the company. -Enters into an in-licensing pact with Euroresearch for introducing Gelfix Collagen dressing sponge pads in the country. -Appoints Mr Nitin Jaywant as the President, Active Pharmaceutical Ingredients division. -Floats a new division called 'SynX' to cater to patients suffering from condition called Syndrome X . -Enters into a research pact with Chiron Corporation of US for contract research. -Gets approval from DCGI to manufacture and market Cefetamet Pivoxil tablets. -Ties up with Italian Pharma company, Euroresearch to bring its products to India. 2003 -Launches 4th generation injectable Cephalosporin Cefepime under the brand name of Cepime. -Allots equity shares to the shareholders of M/s Darshak Ltd as per the scheme of demerger. -Acquires brand and trade mark rights of obstretical care drug Yutopar from Solvay Pharmaceuticals BV, Netherlands. -Launches new division for research and development services, BioArc Research Solutions. -Forays into speciality therapeutics segment. -Signs agreement with two MNC companies for R & D division. -Lines up a rights issue of Rs.32.37crs. -Alembic Limited has informed the Exchange that the company has despatched the Offer Document and Composite application form to all the shareholders on December 22, 2003. The Rights Issue is going to open on December 30, 2003, the last date for receiving requests for split forms is January 13, 2004 and the Rights Issue will close on January 28, 2004. -The comnpany raised Rs 10 crore by placing 90-day commercial paper (CP) at 4.85 per cent with a mutual fund on March 8th. -Alembic signs MoU with Xechem International 2005 - Launches a no-calorie sugar substitute, `Zero', on February 2, 2005. 2006 -Company has splits its Face value of Shares from Rs 10 to Rs 2 2008 - Alembic Ltd has informed that the Company has acquired API manufacturing unit of Nirayu Pvt Ltd. situated at Panelav, P.O. Tajpura, Taluka Halol, Dist. Panchmahals, Gujarat. 2009 -Alembic has recommended dividend at 20% 2010 -Mr. Milin Mehta has been appointed as additional Independent Director of the company. 2011 -Mr. Ashok Tulankar has been appointed as Vice President - Production as Additional Director & Whole-Time Director on the Board of the Company 2012 -Mr. Chandrashekhar P. Buch has been appointed as an Additional - Non-Executive Independent Director of the Company 2013 -Alembic Ltd has allotted 13,35,15,914 Bonus Shares in the ratio of 1:1. -Alembic Ltd has appointed Mr. R. C. Saxena, as Additional Non-Executive Independent Director. -The Board has recommended a dividend of Re. 0.20 (10%) per Equity Share of Rs. 2 each -Alembic has announces Bonus in the Ratio of 1:1 2014 -Alembic Ltd has recommended a dividend of Re. 0.15/- (7.5%) per Equity Share of Rs. 2 each. 2018 -"HGS Wins NASSCOM Customer Service Excellence Award 2018 in Transformation Category". 2020 -Alembic gets USFDA nod for generic ophthalmic solution.

Read More

Parent Organisation

Alembic Ltd.

Founded

30/07/1907

Managing Director

Mrs.Malika Amin

NSE Symbol

ALEMBICLTDEQ

FAQ

The current price of Alembic Ltd is ₹ 92.59.

The 52-week high for Alembic Ltd is ₹ 94.69 and the 52-week low is ₹ 92.30.

The market capitalization of Alembic Ltd is currently ₹ 2377.54. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Alembic Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Alembic Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alembic Ltd shares.

The CEO of Alembic Ltd is Mrs.Malika Amin, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT